GUCY2C-CD3 Antigen-Binding Molecule for Targeted T-Cell Tumor Killing

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current immunotherapies targeting GUCY2C and CD3 for gastrointestinal cancers, such as colorectal and gastric cancers, lack specificity and efficacy in activating immune responses against tumor cells.

Innovation Solution

Development of an antigen-binding molecule that specifically binds to GUCY2C and CD3, comprising defined heavy and light chain variable regions, to enhance T cell activation and immune response against tumor cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current immunotherapies target GUCY2C and CD3 for gastrointestinal cancers, then immune response activation is attempted, but specificity and efficacy are insufficient

Engineering Contradiction:

Improvespecificity and efficacy of immune response activationVSAvoidapplicability to different gastrointestinal cancer types

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The immunotherapy is divided into two separate antigen-binding molecules: one specifically targeting GUCY2C on tumor cells and another targeting CD3 on T cells. This segmentation allows each molecule to be optimized for its specific target, improving overall specificity and efficacy while maintaining adaptability across different cancer types through modular design

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent introduces intermediary molecules that facilitate the interaction between T cells and tumor cells. The GUCY2C-targeting antibody acts as a bridge to present tumor antigens to CD3-targeting T cell activators, creating a controlled immune synapse that enhances both specificity and therapeutic efficacy

Inventive Principle:

Principle #24Intermediary (Mediator)

2Productivity

If bispecific antibodies target both T cells and tumor cells simultaneously, then lytic synapse formation is achieved, but complex structural requirements increase development difficulty

Engineering Contradiction:

Improvetumor cell killing efficiencyVSAvoidstructural complexity of antigen-binding molecule

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

Instead of using a single complex bispecific antibody, the invention segments the function into two separate monoclonal antibodies: one for GUCY2C and one for CD3. Each antibody has a simpler, well-defined structure that is easier to produce and characterize, while collectively achieving the same tumor-killing effect through coordinated action

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent merges the functions of two separate antibodies into a coordinated therapeutic system. The GUCY2C antibody and CD3 antibody work together to form immune synapses and induce tumor cell death, achieving the productivity of a bispecific antibody with the manufacturing simplicity of two separate monoclonal antibodies

Inventive Principle:

Principle #5Merging (Combining)

Data Source

PatentUS20260028421A1Antigen-binding molecule specifically binding to GUCY2c and CD3 and pharmaceutical use thereof

Publication Date: 2026.01.29 JIANGSU HENGRUI MEDICINE CO LTD

AI summary

Provided are an antigen-binding molecule specifically binding to GUCY2C and CD3 and pharmaceutical use thereof. The antigen-binding molecule can be used for treating tumor.